Biopharmaceutical Market Analysis
The global biopharmaceutical market is poised for remarkable expansion, with a projected market size of USD 1039.14 billion by 2032, up from USD 486.15 billion in 2023, reflecting a strong CAGR of 8.82%. This growth trajectory is fueled by groundbreaking advancements in biotechnology, gene therapy, vaccine development, and precision medicine, reshaping the landscape of modern healthcare.
At the core of this dynamic growth lies innovation in biologics and regulatory initiatives that fast-track drug approvals. The proliferation of next-generation treatments—including monoclonal antibodies, gene therapies, and personalized medicines—is addressing long-standing challenges in chronic and rare disease management. Government and private sector investments are bolstering R&D pipelines, while global collaborations accelerate clinical development and access to cutting-edge therapies.
Get a Free Sample Report of Biopharmaceutical Market@ https://www.snsinsider.com/sample-request/4184
One of the most influential recent developments was Zydus Lifesciences’ February 2025 launch of VaxiFlu-4, India’s first quadrivalent influenza vaccine, formulated per WHO recommendations. This vaccine represents a leap in flu prevention, demonstrating how regional innovation is contributing to the global expansion of the biopharmaceutical market.
Strategic partnerships also play a pivotal role. In January 2024, Barinthus Biotherapeutics joined forces with CEPI and the University of Oxford to develop a vaccine targeting Middle East Respiratory Syndrome (MERS). With an investment commitment of USD 34.8 million, the initiative uses the ChAdOx1 platform—also utilized in COVID-19 vaccines—and signals promising outcomes in Phase 2 trials.
The Role of Biologics and Targeted Therapies
Biologics continue to dominate market share due to their targeted action and effectiveness across multiple disease categories. In 2024, monoclonal antibodies (mAbs) held a commanding 60.05% of the biopharmaceutical market, driven by their efficacy in oncology, immunology, and infectious diseases. Products like Keytruda and Opdivo have become benchmarks in cancer immunotherapy, reflecting soaring demand for highly specific biologics.
Meanwhile, Amneal Pharmaceuticals expanded its biosimilar pipeline with omalizumab—used for severe asthma and allergic conditions—showing how biosimilars are enhancing affordability and accessibility while sustaining innovation.
Notably, gene therapy and CRISPR technologies are setting the stage for transformative care. Vertex and CRISPR Therapeutics’ Exa-cel (Casgevy), a one-time gene therapy for sickle cell disease and beta-thalassemia, received FDA and EMA approvals in 2024, marking a historic achievement in genetic medicine.
Leading Segments and Drug Innovations
Oncology remains the largest therapeutic segment, accounting for 31% of the market in 2024. Rising cancer prevalence, coupled with deep pipelines of biologics and immunotherapies, is driving substantial investment. Innovations like Eli Lilly’s Donanemab, which reduced amyloid plaque by 84% in Alzheimer’s patients, underline the sector’s commitment to targeting high-burden diseases.
The hormone therapy segment is emerging rapidly, supported by rising incidences of diabetes, obesity, and an aging global population. Long-acting insulin and erythropoietin therapies are gaining traction, with WHO projecting 1.4 billion people over 60 by 2030, up from 1.1 billion in 2023.
Injectable biologics remain dominant, accounting for 92.35% of formulations due to their systemic action and efficacy. Innovations in delivery mechanisms, such as prefilled syringes and auto-injectors, are improving patient compliance. Inhalation and nasal delivery are gaining ground, particularly in respiratory and neurological treatments. The October 2024 launch of the Ultra Soft Nasal Pump Spray by Aero Pump and Resyca is a key advancement in non-invasive drug delivery.
Drug Development and Distribution Trends
Outsourced drug development comprised 56.19% of the market in 2024, as CDMOs and CROs help companies reduce costs and speed up innovation. In-house development remains strong among major pharmaceutical firms, enabling full control over proprietary research and commercialization.
Branded biologics continued to dominate, making up 77.82% of the market in 2024, buoyed by high R&D investments and robust patent portfolios. However, the biosimilars segment is the fastest-growing, as leading players capitalize on patent expirations. Biocon’s 2024 FDA approval for its Yesafili biosimilar is a prime example.
Prescription-based therapies accounted for 96.85% of sales in 2024, reflecting the specialized nature of biopharmaceuticals. However, OTC products are also gaining relevance in areas such as allergy, cold, and pain management.
In terms of distribution, non-retail channels—such as hospitals and specialty clinics—commanded 55.70% of market share, driven by the complexity of biologic storage and administration. Retail pharmacies are increasingly important for self-administered biologics, expanding access to a wider patient base.
Regional and Competitive Outlook
North America led the global biopharmaceutical market in 2024, propelled by high R&D funding, favorable regulatory pathways, and widespread adoption of monoclonal antibodies and RNA-based therapies. The region benefits from robust healthcare infrastructure and a strong network of hospital pharmacies managing biologic distribution.
Leading players shaping the global landscape include Pfizer Inc., Merck & Co., Roche Holding, Johnson & Johnson, Novartis AG, Sanofi, AstraZeneca, Bristol-Myers Squibb, GSK, Amgen, and Biogen. These companies continue to drive innovation through partnerships, clinical breakthroughs, and strategic M&As.
Recent Industry Milestones
February 2025: Celltrion Inc. received EC approval for Avtozma (CT-P47), a biosimilar to RoActemra.
January 2025: Teva and Samsung Bioepis partnered on EPYSQLI (biosimilar to Soliris) for the US market.
September 2024: Regeneron’s Dupixent gained approval in China for moderate-to-severe atopic dermatitis.
September 2024: Astellas secured conditional approval for Veozah to treat menopause-related symptoms in Japan.
The biopharmaceutical market is entering a new era of growth, marked by rapid innovation, robust investments, and expanding global demand for biologics and gene therapies. As companies forge ahead with strategic collaborations, patient-centric drug development, and advanced delivery platforms, the industry is well-positioned to address unmet medical needs and transform global healthcare outcomes.
Buy a Single-User PDF of Biopharmaceutical Market Analysis & Outlook Report 2024-4184@ https://www.snsinsider.com/checkout/4184
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
6. Competitive Landscape
7. Biopharmaceutical Market by Type
8. Biopharmaceutical Market by Application
9. Regional Analysis
10. Company Profiles
11. Use Cases and Best Practices
12. Conclusion
Read Our Other Report
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
